**Clinical Trial in Colorectal Cancer**

**Currently Enrolling Patients**

**The SIRFLOX Trial**

*SIR-Spheres*®  
**+ FOLFOX**  
**versus**  
**FOLFOX Alone**

(with or without bevacizumab) in Patients with

Unresectable Liver Metastases from Colorectal Cancer

**Randomized controlled trial evaluating SIR-Spheres microspheres in combination with FOLFOX chemotherapy vs. FOLFOX chemotherapy alone for the first-line treatment of unresectable liver-only or liver-predominant colorectal cancer metastases.**

**Purpose:** To assess the efficacy and safety of adding targeted radiation, in the form of SIR-Spheres microspheres, to a standard-of-care systemic chemotherapy regimen of FOLFOX6m (with or without bevacizumab), compared to FOLFOX6m chemotherapy (with or without bevacizumab) alone as first-line therapy in patients with non-resectable liver metastases from primary colorectal adenocarcinoma, with or without evidence of extra-hepatic metastases. Bevacizumab is allowed at the treating investigator’s discretion.

**Trial Design:** Prospective open-label, multi-center, multi-national randomized, controlled trial.

**Eligible Patients:**
- Unresectable liver-only or liver-predominant colorectal cancer metastases
- No prior chemotherapy for advanced disease
- Fit for combination therapy and selective internal radiation therapy (SIRT)

**Schema:**

<table>
<thead>
<tr>
<th><strong>SIR-Spheres microspheres</strong></th>
<th><strong>Randomize 1:1</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FOLFOX6m ± bevacizumab</strong></td>
<td><strong>n = 450</strong></td>
</tr>
</tbody>
</table>

**Stratify**
- Presence of extra-hepatic metastases
- Degree of liver involvement
- Institution
- Use of bevacizumab

**ClinicalTrials.gov Identifier:** NCT00724503

**Study Population:**
- **n = 450**

**Primary Endpoint:**
- Progression free survival, with analysis of overall PFS and PFS in the liver alone

**Secondary Endpoints:**
- Overall survival
- Tumor response rate (liver ± any site)
- Hepatic and extra-hepatic recurrence rate
- Health-Related Quality of Life
- Liver resection rate
- Toxicity and safety

---

This information concerns a use that has not been approved or cleared by the Food and Drug Administration (FDA).

This clinical investigation is being conducted in the USA under an Investigational Device Exemption (IDE) issued by the FDA. SIR-Spheres microspheres are indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intra-hepatic artery chemotherapy (IHAC) of FUdR (5-fluorouracil) under a Food and Drug Administration (FDA) approved premarket application (PMA).

SIR-Spheres microspheres are approved in Australia, the European Union (CE Mark) and several other countries for the treatment of patients with advanced non-operable liver cancer.
Key Inclusion Criteria:
- Histologically confirmed adenocarcinoma of the colon or rectum
- Unequivocal and measurable CT evidence of liver metastases which are not treatable by surgical resection or local ablation with curative intent
- Limited extra-hepatic metastases in the lung (≤5 at ≤1 cm diameter) and/or abdominal lymph nodes (≤2 cm diameter) are permitted
- Adequate hematological, renal and hepatic function
- WHO Performance Status 0 – 1
- Life expectancy >3 months without any active treatment

Key Exclusion Criteria:
- Evidence of ascites, cirrhosis, portal hypertension, main portal venous tumor involvement or thrombosis
- Any extra-hepatic metastases other than lung (≤5 at ≤1 cm diameter) and abdominal lymph nodes (≤2 cm diameter)
- Prior chemotherapy for metastatic colorectal cancer (adjuvant chemotherapy for colorectal cancer is permitted provided that it was completed ≥6 months before trial entry)
- Other active malignancy or prior chemotherapy for any other malignancy
- Previous radiotherapy delivered to the upper abdomen
- Peripheral neuropathy > grade 1 (NCI-CTCv3)
- Pregnant or breast feeding

Participating Countries:
- Australia
- European Union
- New Zealand
- USA

The FOXFIRE Trial:
A similar multi-center Phase III randomized controlled trial is being conducted in the UK. This National Cancer Research Institute trial is sponsored by University of Oxford and supported by The Bobby Moore Fund for Cancer Research UK and Sirtex. The FOXFIRE trial commenced recruitment late 2009 and is structured so that it can be combined with the SIRFLOX trial, allowing for combined analysis of data on safety and efficacy outcomes.2

For More Information Contact:
Australia, New Zealand and USA
info@sirtex.com
info@sirtex-europe.com

Local Treating Center:
This information is intended for clinical investigators and other interested physicians who may wish to enrol or refer patients into this trial. Not for distribution to potential or currently enrolled study subjects.

References: